Author:
Li Anpeng,Li Xiang,Zou Jihua,Zhuo Xiaobin,Chen Shuai,Chai Xiaoyun,Gai Conghao,Xu Weiheng,Zhao Qingjie,Zou Yan
Subject
Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry
Reference46 articles.
1. Targeting RAS signalling pathways in cancer therapy;Downward;Nat Rev Cancer.,2003
2. L. Therachiyil, A. Anand, A. Azmi, A. Bhat, H.M. Korashy, S. Uddin, Role of RAS signaling in ovarian cancer, F1000Res. 11 (2022) 1253. 10.12688/f1000research.126337.1.
3. Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas;Schnleben;Journal of Gastrointestinal Surgery.,2009
4. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation;Avery;Front Oncol.,2022
5. GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition;Gilmartin;Clinical Cancer Research.,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献